2009/10 Half-Year Report

Your Specialist for Hazardous Reactions.

Content

Dear Shareholder,

We are pleased to present DOTTIKON ES Group's Half-Year Report for the period from April 1 to September 30, 2009.

The period under review was characterized by the ongoing worldwide recession. The virtual freefall in demand for industrial chemicals has bottomed out at a low level and reached a floor. For some basic chemicals, even a slight increase was observed in the second quarter. This growing demand is primarily attributable to the previous overshooting destocking. Though some basic raw materials have seen price increases – not least due to speculative transactions – it is still too early to talk of a recovery across the economy as a whole. It remains to be seen whether the positive trend shown by leading indicators will develop into a lasting economic recovery beyond the end of many government support programs. Governments' objective of using these measures to support private consumption has been achieved in the short term. However, a reduction in end-consumer demand has to be anticipated as a result of increasing unemployment. Unemployment rates have reached 10 percent or more in many countries and are still rising. The future interplay between supply, inventory levels, production volumes, demand and the resulting consequences for the economic recovery will be crucially dependent on the intensity of a decline in end-consumer demand.

KEY FIGURES, APRIL–SEPTEMBER

CHF million (unaudited)	2008	2009	Changes
Net sales	78.2	45.3	-42.1%
EBITDA	24.0	11.9	-50.2%
EBITDA margin (in % of net sales)	30.6%	26.3%	
EBIT	17.3	5.2	-69.9%
EBIT margin (in % of net sales)	22.2%	11.5%	
Net income	14.5	4.7	-67.9%
Net income margin (in % of net sales)	18.6%	10.3%	
Operating cash flow	29.8	18.0	-39.7%
Employees (FTEs, six-month average)	470	455	-3.2%

Owing to missing new product launches, the loss of sales due to patent expirations and government regulation of drug prices, innovation, price and margin pressures on pharmaceutical and generics firms continued to mount in the period under review. The pharmaceutical companies are keeping a more watchful eye on cash reserves and their use. In the period under review, therefore, the inventories that had been accumulated in order to ensure deliveries in a pandemic scenario were reduced massively, expenditure on pharmaceutical project pipelines was reviewed – including external replacement and completion opportunities – while development activities and attendant costs were increasingly switched from early to later clinical development stages. The resources thus freed up are being used for the acquisition of biotech firms that are struggling financially, and for cross- and in-licensing their projects. But many pharmaceutical companies are also questioning the "last mile" – completing the final steps of active pharmaceutical ingredient (API) production in-house – and in some cases have already given this up. They are also aiming for a reduction in the number of suppliers along the value chain and for each individual project. The companies are initiating measures to reduce time-to-market, the effects of which, however, are not yet apparent.
In light of these tensions, the complexity and financial risks in process development and exclusive synthesis for pharmaceutical companies are increasing. Proven experience, rapid adaptability, innovative process technology, and reliability when it comes to quality and supply are becoming the key success factors in such an environment. The pharmaceutical companies will increasingly concentrate on their core competencies of clinical research and development, patenting and distribution, and will boost and strengthen strategic cooperation with experienced, innovative, and reliable partners in process development and API production.

Albeit stunted at present due to current economic circumstances, the demand for high-quality, sophisticated exclusive synthesis under time pressure – in other words, the demand for capacity for the development of safe and stable chemical processes with hazardous reactions and high-volume capacity for multiton API production employing these processes in compliance with the highest standards of safety and pharmaceutical quality – is set to increase sharply again going forward. We therefore forged ahead with expanding capacity in the first half of the business year. In medium-scale production, the installation of API separator capacity was expanded and brought on stream. In large-volume production, we expanded in this reporting period our corrosion-resistant glass-lined steel and Hastelloy multipurpose reactor, low-temperature, and API separator capacity. After initial technical delays, they were brought on stream successfully. At CHF 45.3 million, net sales were considerably lower in the first half of the business year compared with the same period of the previous year. This was due to the previously announced elimination of redundant product lines and delayed commissioning of new apparatus groups. Costs were aligned with the lower net sales for the period under review, with the result that – taking into account the divesture of property in the same period of the previous year – EBITDA margins were maintained. Personnel expenses were reduced by around 9 percent compared with the same period of the previous year, with headcount falling 3 percent. Significantly lower material expenses reflected the enhanced product mix. Earnings fell significantly as a result of the considerable decline in net sales, even when taking the extraordinary effects in the same period of the previous year into account.

The implementation and build-on of our strategy – performance leadership as specialist for hazardous reactions – will continue. DOTTIKON ES continues to focus on high flexibility, speed, safety, and reliability.

In the current business year 2009/10, we will continue to invest in high-quality, technologically advanced capacity expansion. Owing to the previously announced elimination of redundant product lines, we expect lower net sales on an enhanced product mix for the full business year 2009/10 in comparison to the previous year.

Dottikon, November 19, 2009

Dr Markus Blocher
Chief Executive Officer

Financial Report

Consolidated Income Statements

April–September
CHF thousand and % (unaudited)
Notes, No 1

[A] There are no options or similar that have a dilutive effect

	2008	%	2009	%
Net sales	**78'237**	**100.0**	**45'291**	**100.0**
Changes in semi-finished and finished goods	4'855		7'664	
Other operating income	6'512		2'790	
Material expenses	-31'154		-14'302	
Personnel expenses	-25'148		-22'832	
Other operating expenses	-9'348		-6'677	
EBITDA	**23'954**	**30.6**	**11'934**	**26.3**
Depreciation and amortization	-6'614		-6'720	
EBIT	**17'340**	**22.2**	**5'214**	**11.5**
Financial income	1'103		239	
Financial expenses	-826		-149	
Financial result	**277**		**90**	
Result from associated companies	**0**		**0**	
Net income before taxes	**17'617**	**22.5**	**5'304**	**11.7**
Income taxes	-3'103		-649	
Net income	**14'514**	**18.6**	**4'655**	**10.3**
Basic earnings per share in CHF[A]	**11.73**		**3.76**	
Weighted average number of shares	**1'237'265**		**1'237'101**	

Consolidated Statement of Comprehensive Income

April–September
CHF thousand (unaudited)

	2008	2009
Net income	**14'514**	**4'655**
Realized gains (losses) on foreign exchange forwards	-1'299	67
Changes in fair value of foreign exchange forwards	-20	-199
Income taxes on other comprehensive income	288	27
Other comprehensive income, net of taxes	**-1'031**	**-105**
Total comprehensive income	**13'483**	**4'550**

Consolidated Balance Sheets

CHF thousand and % (unaudited)
Notes, No 2

	31.03.2009	%	30.09.2009	%
Intangible assets	47		54	
Property, plant and equipment	222'872		229'285	
Investments in associated companies	1'068		1'068	
Financial assets	17'454		17'533	
Non-current assets	**241'441**	**66.8**	**247'940**	**68.7**
Inventories	54'395		62'253	
Trade receivables	32'590		13'718	
Other receivables	2'511		3'240	
Cash and cash equivalents	30'395		33'898	
Current assets	**119'891**	**33.2**	**113'109**	**31.3**
Assets	**361'332**	**100.0**	**361'049**	**100.0**
Share capital	6'363		6'363	
Share premium	60'406		60'455	
Own shares	-7'426		-7'057	
Retained earnings	238'554		243'104	
Shareholders' equity	**297'897**	**82.4**	**302'865**	**83.9**
Deferred tax liabilities	38'300		38'562	
Non-current liabilities	**38'300**	**10.6**	**38'562**	**10.7**
Trade payables	6'396		3'782	
Income tax liabilities	5'018		4'010	
Other current liabilities	13'721		11'830	
Current liabilities	**25'135**	**7.0**	**19'622**	**5.4**
Liabilities	**63'435**	**17.6**	**58'184**	**16.1**
Shareholders' equity and liabilities	**361'332**	**100.0**	**361'049**	**100.0**

Consolidated Cash Flow Statements

April–September
CHF thousand (unaudited)
Notes, No 3

[A] Cash and bank accounts:
CHF 33'898 thousand (previous year: CHF 16'085 thousand)
Fixed deposits (original maturity of up to 90 days):
CHF 0 thousand (previous year: CHF 23'000 thousand)

	2008	2009
Net income	14'514	4'655
Income taxes	3'103	649
Financial result	-277	-90
Depreciation of property, plant and equipment	6'565	6'694
Amortization of intangible assets	49	26
Result from associated companies	0	0
Other non-cash income and expenses	-2'464	609
Interest received	305	21
Interest paid	-11	-7
Income taxes paid	-2'182	-1'370
Changes in		
Trade receivables	9'389	18'713
Other receivables	512	-830
Inventories	2'188	-7'858
Trade payables	-3'611	-1'535
Other current liabilities	1'757	-1'681
Cash flow from operating activities	**29'837**	**17'996**
Additions to		
Intangible assets	0	0
Property, plant and equipment	-14'390	-14'471
Financial assets	0	0
Disposals of		
Intangible assets	0	0
Property, plant and equipment	4	4
Financial assets	160	0
Payment receipt related to non-current assets held for sale	8'150	0
Cash flow from investing activities	**-6'076**	**-14'467**
Dividends paid	0	0
Purchase of own shares	-45	0
Disposal of own shares	0	0
Cash flow from financing activities	**-45**	**0**
Currency translation effect on cash and cash equivalents	61	-26
Net change in cash and cash equivalents	**23'777**	**3'503**
Cash and cash equivalents at the beginning of the reporting period	15'308	30'395
Cash and cash equivalents at the end of the reporting period[A]	**39'085**	**33'898**

Consolidated Statement of Changes in Equity

CHF thousand (unaudited)

	Share capital	Share premium	Own shares	Changes in fair value of foreign exchange forwards (including tax impact)	Other retained earnings	Shareholders' equity
Balance 01.04.2008	**6'363**	**60'321**	**-7'296**	**1'122**	**216'510**	**277'020**
Net income					**14'514**	**14'514**
Realized gains (losses) on foreign exchange forwards				-1'299		-1'299
Changes in fair value of foreign exchange forwards				-20		-20
Income taxes on other comprehensive income				288		288
Other comprehensive income, net of taxes				**-1'031**		**-1'031**
Total comprehensive income				**-1'031**	**14'514**	**13'483**
Changes in own shares		86	198			284
Balance 30.09.2008	**6'363**	**60'407**	**-7'098**	**91**	**231'024**	**290'787**
Balance 01.10.2008	**6'363**	**60'407**	**-7'098**	**91**	**231'024**	**290'787**
Net income					**7'595**	**7'595**
Realized gains (losses) on foreign exchange forwards				-133		-133
Changes in fair value of foreign exchange forwards				-61		-61
Income taxes on other comprehensive income				38		38
Other comprehensive income, net of taxes				**-156**		**-156**
Total comprehensive income				**-156**	**7'595**	**7'439**
Changes in own shares		-1	-328			-329
Balance 31.03.2009	**6'363**	**60'406**	**-7'426**	**-65**	**238'619**	**297'897**
Balance 01.04.2009	**6'363**	**60'406**	**-7'426**	**-65**	**238'619**	**297'897**
Net income					**4'655**	**4'655**
Realized gains (losses) on foreign exchange forwards				67		67
Changes in fair value of foreign exchange forwards				-199		-199
Income taxes on other comprehensive income				27		27
Other comprehensive income, net of taxes				**-105**		**-105**
Total comprehensive income				**-105**	**4'655**	**4'550**
Changes in own shares		49	369			418
Balance 30.09.2009	**6'363**	**60'455**	**-7'057**	**-170**	**243'274**	**302'865**

Notes

Corporate Accounting Principles (condensed)

BASIS OF PREPARATION OF THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The consolidated interim financial statements comprise DOTTIKON ES HOLDING AG and all entities which the holding directly or indirectly controls either by holding more than 50 percent of the voting rights or by having otherwise the power to govern their operating and financial policies. These entities are fully consolidated. The consolidation is based on the individual financial statements of the subsidiaries prepared on the basis of uniform accounting policies.

Entities, in which DOTTIKON ES Group holds at least 20 percent of the voting rights, but less than 50 percent, or over which it otherwise has significant influence, are accounted for using the equity method and are classified as investments in associated companies.

The consolidated interim financial statements are prepared for the half year ended September 30, 2009 (reporting period), and have been prepared in accordance with the International Accounting Standard 34 (IAS 34) "Interim Financial Reporting". The interim financial statements have not been audited.

These consolidated interim financial statements do not include all information available in the annual financial statements and should therefore be read in conjunction with the group financial statements for the year ended March 31, 2009.

The preparation of the consolidated interim financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, and the disclosure of contingent liabilities at the date of the consolidated interim financial statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the consolidated interim financial statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

No new significant estimates and assumptions were made in these consolidated interim financial statements compared to the consolidated financial statements for the year ended March 31, 2009.

Income tax expense is recognized based upon the best estimate of the weighted average annual income tax rate expected for the full business year.

CHANGES IN CORPORATE ACCOUNTING PRINCIPLES

The interim financial statements have been prepared in accordance with the accounting policies set out in the annual financial statements 2008/09, except for the following:

With effect from April 1, 2009, DOTTIKON ES Group adopted the newly issued IFRS 8 "Operating Segments", IFRIC 13 "Customer Loyalty Programmes", IFRIC 15 "Agreements for the Construction of Real Estate", IFRIC 16 "Hedges of a Net Investment in a Foreign Operation" and IFRIC 18 "Transfers of Assets from Customers" (transactions on or after July 1, 2009) as well as the revised IFRS 2 "Share-based Payment – Vesting Conditions and Cancellations", IFRS 7 "Financial Instruments: Disclosures: Enhanced Disclosures about Fair Value Measurements and Liquidity Risk", IAS 1 "Presentation of Financial Statements", IAS 23 "Borrowing Costs", IAS 32 "Financial Instruments: Presentation and IAS 1 – Presentation of Financial Statements – Puttable Financial Instruments and Obligations Arising on Liquidation" as well as IFRIC 9 and IAS 39 "Embedded Derivatives".

Those revised or new standards and interpretations – with the exception of IFRS 8 and IAS 1 revised – did not have a significant impact on equity, net income, and cash flow of the Group.

The adoption of IFRS 8 "Operating Segments" led to a material change with regard to disclosure of operating segments as well as to enhanced entity-wide disclosures. The adoption of IAS 1 revised "Presentation of Financial Statements" led to additions and changes in the presentation of comprehensive income and the statement of changes in equity. The disclosure of the previous year's figures has been restated accordingly.

STANDARDS THAT HAVE BEEN ISSUED BUT NOT YET APPLIED

The following new and revised standards and interpretations have been issued up to the date the Board of Directors has approved these consolidated financial statements, but are not yet effective and are not applied early in these consolidated interim financial statements. Their impact on the consolidated financial statements of DOTTIKON ES Group has not yet been systematically analyzed. The expected effects as disclosed below the table, reflect a first assessment by management of the Group.

Standard/Interpretation		Effective date	Planned application by DOTTIKON ES Group
IFRS 3 revised – Business Combinations	C	July 1, 2009	Business year 2010/11
Improvements to IFRSs	C	July 1, 2009	Business year 2010/11
IAS 27 revised – Consolidated and Separate Financial Statements	C	July 1, 2009	Business year 2010/11
Amendments to IAS 39 – Financial Instruments: Recognition and Measurement – Eligible Hedged Items	A	July 1, 2009	Business year 2010/11
IFRIC 17 – Distributions of Non-cash Assets to Owners	A	July 1, 2009	Business year 2010/11
Amendments to IFRS 2 – Group Cash-settled Share-based Payment Transactions	A	January 1, 2010	Business year 2010/11
Improvements to IFRSs	C	January 1, 2010	Business year 2010/11
Amendment to IAS 32 – Financial Instruments: Presentation – Accounting for Rights Issues	A	February 1, 2010	Business year 2010/11
IAS 24 revised – Related Party Disclosures	C	January 1, 2011	Business year 2011/12
IFRS 9 – Financial Instruments – Classification and Measurement of Financial Assets	C	January 1, 2013	Business year 2013/14

[A] No impact or no significant impact is expected on the consolidated financial statements of DOTTIKON ES Group

[B] The impact on the consolidated financial statements of DOTTIKON ES Group is expected to result in additional disclosures or changes in presentation

[C] The impact on the consolidated financial statements of DOTTIKON ES Group cannot yet be determined with sufficient reliability

Notes to the Consolidated Interim Financial Statements (condensed)

1 INCOME STATEMENT

Net sales decreased by CHF 32.9 million to CHF 45.3 million compared to the same period of the previous year. This decrease was due to the announced elimination of redundant product lines and delayed commissioning of new apparatus groups in large-volume production due to technical issues. The increase in semi-finished and finished goods of CHF 7.7 million in connection with preparatory efforts – for products to be delivered in the second half of the business year 2009/10 – was CHF 2.8 million higher in the reporting period than in the same period of the previous year. Material expenses decreased by CHF 16.9 million compared to the same period of the previous year due to lower net sales on an enhanced product mix.

In the same period of the previous year, other operating income was mainly influenced by the extraordinary effect of the disposal of "property which is being held for sale" by CHF 4.5 million. In the reporting period, other operating income includes claims – related to the delayed commissioning of new apparatus groups – of CHF 0.8 million.

In connection with the announced elimination of redundant product lines and with the delayed commissioning of new apparatus groups, personnel expenses decreased by CHF 2.3 million.

Other operating expenses were reduced by CHF 2.7 million as a result of cost efficiencies. In the same period of the previous year, other operating expenses included costs ineligible for capitalization in connection with investing activities and extraordinary expenses caused by the disposal of "property which is being held for sale".

Depreciation rose by CHF 0.1 million to CHF 6.7 million in the reporting period. Ordinary depreciation rose due to intensified investments in high-quality, technologically advanced plant components. In the same period of the previous year, the position included additional depreciation of CHF 0.9 million due to decreased useful lives of several technical plant and machinery in connection with the investment activity.

EBIT decreased by CHF 12.1 million to CHF 5.2 million due to lower net sales because of delayed commissioning of new apparatus groups due to technical issues and the extraordinary effect of the disposal of "property which is being held for sale" in the same period of the previous year.

The associated company (SYSTAG, System Technik AG) reports its figures once a year for the Annual Report as of March 31. The impact on the Group's equity and net income is not material and will therefore only be considered in the Annual Report as of March 31.

Income tax expenses showed a disproportionate decrease of CHF 2.5 million in the reporting period due to lower net income.

The Group's operations are not subject to significant seasonal fluctuations.

2 BALANCE SHEET

Non-current assets increased by CHF 6.5 million in the reporting period. This rise was mainly due to intensified investments in high-quality, technologically advanced capacity expansion. The corresponding additions amount to CHF 13.5 million and led to a cash outflow of CHF 14.5 million in the reporting period.

Financial assets include the surplus of pension assets. An independent certified actuary estimated the recoverability of the capitalized surplus as of September 30, 2009. No significant impact was noted.

Current assets decreased by CHF 6.8 million compared to end of March 2009. Trade receivables decreased by CHF 18.9 million in the reporting period due to the consistent reduction and lower net sales. The inventory build-up of CHF 7.9 million primarily results from higher semi-finished and finished goods, for products to be delivered in the second half of the business year 2009/10. Cash inflow from operating activities of CHF 18.0 million less cash outflow from investing activities of CHF 14.5 million led to an increase in cash and cash equivalents by CHF 3.5 million in the reporting period.

Shareholders' equity increased by CHF 5.0 million compared to end of March 2009, and now amounts to CHF 302.9 million as of end of September 2009. The equity ratio is 83.9 percent as of end of September 2009, representing a marginal increase. This rise in shareholders' equity is mainly due to the Group's net income of CHF 4.7 million. In the first half of the business year, transactions with own shares resulted in a net reduction for the acquirement of gratuity shares for employees, which DOTTIKON ES Group considers being performance drivers.

Current liabilities decreased by CHF 5.5 million compared to March 2009. This is due to a decrease of CHF 2.6 million in trade payables, as a result of lower material expenses and other operating expenses, as well as the decrease of CHF 1.9 million in other current liabilities.

3 CASH FLOW STATEMENT

Cash flow from operating activities decreased by CHF 11.8 million compared to the same period of the previous year and amounts to CHF 18.0 million in the reporting period. This mainly results from the decrease of net sales due to the delayed commissioning of new apparatus groups due to technical issues, the inventory build-up of CHF 10.0 million, as well as the consistent reduction in trade receivables of CHF 9.3 million compared to the same period of the previous year. In the reporting period, other non-cash income and expenses mainly resulted from the loss on disposal of non-current assets, as well as from unrealized foreign currency gains/losses (same period of the previous year: impacted by employer contributions for the pension plan amounting to CHF 1.4 million – which were financed by the existent employer contribution reserves, hence there was no outflow of funds – and by a gain on the disposal of "property which is being held for sale" of CHF 4.5 million).

In the reporting period, DOTTIKON ES Group's outflow of cash and cash equivalents in investing activities amounts to CHF 14.5 million and was CHF 0.1 million higher than in the same period of the previous year. This rise was due to intensified investments in high-quality, technologically advanced capacity expansion. In the same period of the previous year, the disposal of "property which is being held for sale" generated an inflow of CHF 8.2 million in cash and cash equivalents for DOTTIKON ES Group.

In the reporting year, no dividend was paid to the shareholders of DOTTIKON ES HOLDING AG. The waiver of dividends will be used, as in the previous year, for the intensive capacity expansion activities, which will be continued in the second half of the business year 2009/10.

Cash and cash equivalents rose by CHF 3.5 million in the reporting period and amount to CHF 33.9 million as of end of September 2009.

4 SEGMENT REPORTING

DOTTIKON ES Group is specialized in hazardous chemical reactions and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industry worldwide.

According to IFRS 8 "Operating Segments", the reportable operating segments are determined using the management approach. External segment reporting is thus based on the Group's internal organization and management structure as well as internal financial reporting to the Chief Operating Decision Maker. DOTTIKON ES Group's Chief Operating Decision Maker is the Board of Directors. In addition to its statutory tasks, the Board of Directors is responsible for the strategic focus and management of the Group. Strategic and important operational decisions of DOTTIKON ES Group are taken by the Board of Directors.

DOTTIKON ES Group builds on a single production site and continues the strategy of performance leadership as specialist for hazardous reactions. DOTTIKON ES Group mainly executes projects with focus on the exclusive synthesis of fine chemicals which are strongly heterogeneous. Therefore a differentiation in several operating segments is not informative.

The financial reporting to the Board of Directors as Chief Operating Decision Maker is prepared in a single segment. DOTTIKON ES Group allocates resources and assesses their performance on entity level.

The segment reporting is compiled according to IFRS 8.31 ff. as one single reportable segment. The valuation principles applied for segment reporting purposes are consistent with those applied in the preparation of the consolidated financial statements.

Entity-wide disclosures are as follows:

Net sales by product lines:

CHF thousand/April–September	2008	2009
Pharma Products	58'813	40'128
Industrial Chemicals	15'879	2'558
Recycling & Waste Treatment	3'545	2'605
Net sales	**78'237**	**45'291**

Net sales by regions:

CHF thousand/April–September	2008	2009
Switzerland	16'144	12'262
Europe and others	40'725	23'321
America	20'132	8'380
Asia	1'236	1'328
Net sales	**78'237**	**45'291**

Share of sales by customers:

CHF thousand/April–September	2008	2009
Customers with more than 10% of net sales[A]	25'285	18'222
Customers with less than 10% of net sales	52'952	27'069
Net sales	**78'237**	**45'291**

[A] Reporting period 2009/10: 3 customers with more than 10% of net sales (same period of the previous year: 2 customers)

5 EVENTS AFTER THE BALANCE SHEET DATE

The consolidated interim financial statements were approved for issue by the Board of Directors on November 19, 2009. No events have occurred between September 30, 2009, and November 19, 2009, that would require an adjustment of the Group's carrying amounts of assets and liabilities or would require disclosure in this note.

Investor Relations

Issue Annual Report 2009/10:
May 28, 2010

Annual General Meeting for the Business Year 2009/10:
July 2, 2010

Issue Half-Year Report 2010/11:
November 26, 2010

DOTTIKON ES HOLDING AG is listed at the SIX Swiss Exchange.
Symbol: DESN
Security number: 2073900
ISIN: CH0020739006

Dottikon ES Holding AG
P.O. Box
5605 Dottikon
Switzerland

Tel +41 56 616 82 01
Fax +41 56 616 89 45
www.dottikon.com

Contact:
Marlene Born, CFO
investor-relations@dottikon.com

DOTTIKON ES Group, with its production site in Dottikon (Aargau, Switzerland), is specialized in hazardous chemical reactions and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industry worldwide. The product range of DOTTIKON ES Group includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates as well as in-house-developed, high-value industrial chemicals.

Dottikon ES Holding AG
P.O. Box, 5605 Dottikon, Switzerland, Tel +41 56 616 82 01, Fax +41 56 616 89 45, www.dottikon.com